Neostem Inc.  (NBS) Trade Now »     Rate NBS  -  Discuss NBS  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

NBS Analysis & Videos »


NBS: Bull or Bear?

FDA Calendar November Stocks: Turkeys or a Happy Thanksgiving? NBS

73%

-19.50% in 17 days <> <> On 7/15/09, Cadence Pharma (NASDAQ: CADX) announced that its New Drug Application (NDA) for Acetavance (intravenous acetaminophen), its investigational product candidate for the treatment of acute pain and fever in adults and children, has been accepted for filing by the FDA and designated for a priority (six-month) review. The FDA has issued a PDUFA action date for the NDA of 11/13/09 for a possible decision by the Agency. The Company's 505(b)(2) NDA for Acetavance includes data from one pivotal clinical trial for the treatment of acute pain in patients following orthopedic surgery and ... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  10/25/09

1 comment

A Three-Part China Merger Strategy for NeoStem (AMEX: NBS) NBS

73%

+5.26% in 17 days (closed on 10/25/09) NeoStem (AMEX: NBS) is an innovator and leader in the pre-disease collection, processing and long-term storage of adult stem cells for the general population to use in future medical applications that is expanding into research, medical tourism, and China for the commercialization of anti-aging / cosmetic medicine and other stem cell technologies. Click here for my mid-September article , which provides an overview and details on the pending China expansion plans as part of a merger that is expected to close by the end of October. <o:p> </o:p> <> <> <o:p>   </o:p> <><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  10/08/09

1 comment

NeoStem (AMEX: NBS): Pending Merger Key to China Growth Strategy NBS

73%

+1.60% in 22 days (closed on 10/08/09) <> NeoStem (AMEX: NBS) is an innovator and leader in the pre-disease collection, processing and long-term storage of adult stem cells for the general population to use in future medical applications. The Company's business model includes generating revenue through ongoing fees associated with a minimally invasive, proprietary stem cell collection process, in addition to fees charged to the centers for marketing and long-term storage. NeoStem targets its marketing efforts toward health conscious consumers to encourage them to donate and store their stem cells as a form of bio-insurance for... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  09/16/09

Comment

Neostem, Inc. NBS

N/A

-5.29% in 135 days <> NeoStem, Inc. (NeoStem), incorporated in September 1980, is engaged in a platform business of operating a commercial autologous (donor and recipient are the same) adult stem cell bank and in pre-disease collection, processing and long-term storage of stem cells from adult donors that they can access for their own future medical treatment. The Company manages a network of adult stem cell collection centers throughout the United States. It also entered the research and development arenas, through the acquisition of a worldwide license to an early-stage technology to ident... Continue reading »

By  supratrader   (+16.41%  risk: conservative)  06/29/09

Comment

Bullish on NBS ... NBS

62%

-33.47% in 141 days AMEX:NBS) is a pioneer and leader in the pre-disease collection, processing and long-term storage of adult stem cells for the general population to use in future medical applications. The Company's business model includes generating revenue through ongoing fees associated with a minimally invasive, proprietary stem cell collection process, in addition to fees charged to the centers for marketing and long-term storage. The Company was recently profiled at BusinessWeek online and will appear in the June 29 print magazine edition. Continue reading »

By  Marian Filo   (-24.55%  risk: aggressive)  06/23/09

Comment

NeoStem (AMEX:NBS): BusinessWeek Mention NBS

73%

-18.70% in 89 days (closed on 09/16/09)   <font> NeoStem, Inc. </font> (AMEX:NBS)is a pioneer and leader in the pre-disease collection, processing and long-term storage of adult stem cells for the general population to use in future medical applications. The Company's business model includes generating revenue through ongoing fees associated with a minimally invasive, proprietary stem cell collection process, in addition to fees charged to the centers for marketing and long-term storage.   <> The Company was recently <font> profiled at BusinessWeek online </font> and will appear in the June 29 pr... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  06/19/09

Comment

NeoStem (AMEX:NBS): Pro-Active Research Initiates as Spec Buy NBS

73%

-11.54% in 15 days (closed on 06/19/09)   <> <font> NeoStem, Inc. </font> (AMEX:NBS)is a pioneer and leader in the pre-disease collection, processing and long-term storage of adult stem cells for the general population to use in future medical applications. The Company's business model includes generating revenue through ongoing fees associated with a minimally invasive, proprietary stem cell collection process, in addition to fees charged to the centers for marketing and long-term storage. NeoStem targets its marketing efforts toward health conscious consumers to encourage them to donate and store their stem cell... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  06/04/09

Comment

NeoStem Expands Beyond Stem Cell Banking NBS

73%

+38.30% in 17 days (closed on 06/04/09)   <> NeoStem (AMEX:NBS) is a pioneer and leader in the pre-disease collection, processing and long-term storage of adult stem cells for the general population to use in future medical applications. The Company's business model includes generating revenue through ongoing fees associated with a minimally invasive, proprietary stem cell collection process, in addition to fees charged to the centers for marketing and long-term storage. NeoStem targets its marketing efforts toward health conscious consumers to encourage them to donate and store their stem cells as a form of bio-insuran... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  05/18/09

Comment

Stem Cell Index Surges in Past Week NBS

73%

+7.43% in 8 days (closed on 05/18/09) <> The stem cell trade was back in a big way over the past week, with several stocks in the <font> ETF Innovators Stem Cell Index </font> registering impressive gains, compared to market and biotech ETF benchmarks such as the S&P 500 SPDR (NYSE:SPY) +6%, iShares Nasdaq Biotech (NASDAQ:IBB) +2%, SPDR S&P Biotech (NYSE:XBI +4%). Hot stocks over the past week among the 40 component companies in the stem cell index include NeoStem (AMEX:NBS) +52.2%, Cytori Therapeutics (NASDAQ:CYTX) +37%, and Geron (NASDAQ:GERN) +22%. Two other widely followed stocks from the index registered smaller gains,... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  05/10/09

Comment

Stem Cell Index: YTD Analysis, Banking on NeoStem NBS

73%

+45.83% in 29 days (closed on 05/10/09) Related Tickers: NBS, IART, OSIR, STEM, GE, XLV, IBB, XBI, PBE, SPY By Mike Havrilla on 4/11/09 at www.BioMedReports.com Disclosure: No Positions   The ETF Innovators Global Stem Cell and Regenerative Medicine Index tracks the performance of 40 stem cell and regenerative medicine companies on a global basis with market caps of less than $1 billion at the inception of the index. The total market value of the index will be tracked as a gauge of investor and trader sentiment toward stem cell companies from a starting value of 3,928 on 2/22/09.   ... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  04/11/09

Comment

People Bullish on NBS

Mike Havrilla Principal 73% 17 days ago	mjnaber Analyst N/A about 1 mo ago	fannie32 Analyst N/A about 1 mo ago
mvpindia Analyst N/A 2 mos ago	supratrader Principal N/A 4 mos ago

People Bearish on NBS

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.